This prompted us to evaluate the antiproteinuric effect of spironolactone in patients with nephrotic syndrome secondary to idiopathic membranous nephropathy (IMN) and persistent proteinuria despite full dose ACE inhibitor therapy. This evidence concerns the gene ACE and idiopathic membranous glomerulonephritis.